乳房病変局在化市場は、2021年の244百万米ドルから2026年には305百万米ドルに達すると予想されています。この市場の成長は主に、乳がんの発生率の増加、老年人口の増加（年齢が乳がんのリスクに寄与するため）、今後数年間における乳がんの早期発見に対する意識の高まりに起因しています。しかし、規制当局による承認手続きの不確実性などのいくつかの要因が、予測期間中の乳房病変局在化市場の成長を抑制すると予想されています。
本レポートでは、乳房病変部局在化市場をタイプ別、用途別、地域別に分類しています。
2020年の乳房病変部局在化市場では、金額ベースではワイヤー局在化が最大のシェアを占めている
乳房病変局在化市場は、タイプ別に、ワイヤーローカリゼーション、ラジオアイソトープローカリゼーション、磁気ローカリゼーション、電磁ローカリゼーション、その他のローカリゼーション法に分類されます。金額ベースでは、2020年の乳房病変局在化市場において、ワイヤーローカリゼーションが最大のシェアを占めています。異常組織の適切な局在化、正常組織の最小限の除去、最小限の傷跡、乳房病変局在化装置に対する償還の可能性などが、ワイヤー局在化セグメントの成長を促進する主な要因となっています。
ラジオアイソトープローカリゼーション市場では、2020年にRadio-guided occult lesion localization (ROLL)セグメントが最大のシェアを占めている
ラジオアイソトープローカリゼーションは、乳がん手術の際の術前の非触知性病変のローカリゼーションや、がんのステージングにおけるセンチネルリンパ節マッピングに使用されます。放射性同位元素を用いた局在化法は、タイプ別に、Radio-guided occult lesion localization (ROLL)とRadio-seed localization (RSL)に分けられます。2020年の乳房病変局在化市場では、ROLLセグメントが最大のシェアを占めています。
2020年の乳房病変部局在化市場では、乳房生検分野が最大のシェアを占めています。
用途に基づいて、乳房病変局在化法市場は、乳房生検と乳房温存（Lumpectomy）に分けられます。2020年、乳房病変局在化法市場では、乳房生検が最大のシェアを占めています。市場の成長を促進する要因としては、乳がんの発生率の増加、乳がん検診プログラムの増加、償還シナリオの改善、乳がんの早期発見に対する意識の高まり、低侵襲・非侵襲手術への需要の高まりなどが挙げられます。

2020年の乳房病変局在化市場では、北米が最大のシェアを占める
乳房病変部局在化市場は、北米、欧州、アジア太平洋地域（APAC）、その他の地域（RoW）の4つの主要地域に分けられます。
金額ベースでは、2020年の乳房病変部局在化市場では、北米が最大のシェアを占め、欧州がそれに続きます。予測期間中、APAC市場が最も高いCAGRで成長すると予測されています。この市場の成長は主に、患者人口の急増、医療費の増加、医療インフラの整備、乳がん研究への政府支出の増加、APACのいくつかの国で乳がんの早期発見の重要性に対する認識が高まっていることに起因しています。
本レポートでは、自動車用センサー市場で活動する様々な主要組織のCEO（最高経営責任者）、マーケティングマネージャー、その他の幹部に詳細なインタビューを行っています。

- 企業タイプ別に見るとティア1 - 55%、ティア2 - 30%、ティア3 - 15
- 呼称別Cレベルエグゼクティブ - 28%, マネージャー - 33%, その他 - 39
- 地域別欧州 - 20%、アジア太平洋 - 30%、北米 - 35%、およびRoW - 15


乳房病変部局在化市場の主要プレイヤー

乳房病変局在化市場の著名なプレーヤーは、Hologic, Inc.(米国)、Becton, Dickinson and Company (米国)、Merit Medical Systems (米国)、Leica Biosystems Nussloch GmbH (米国)、Argon Medical Devices (米国)、Laurane Medical LLC (フランス)、Endomagnetics Ltd. (英国)、Intramedical Imaging, LLC (米国)、Isoaid (米国)、Surgeyeeye (米国)。(英国）、Intramedical Imaging, LLC（米国）、Isoaid（米国）、Surgiceye GmbH（ドイツ）、Ranfac Corp.(米国）、Mermaid Medical Group（デンマーク）、Izi Medical Products, LLC（米国）、Matek Medikal（トルコ）、Tsunami Medical Srl（イタリア）、BPB Medica（イタリア）、Sirius Medical Systems B.V. （オランダ）、Molli Surgical B．(オランダ)、Molli Surgical Inc.(カナダ)があります。乳房病変局在化市場のその他のプレーヤーは、Sterylab S.R.L.(イタリア)、CP Medical(ジョージア)、MDL SRL(イタリア)、Biomedical Srl(イタリア)、Elucent Medical(米国)、Vigeo srl(イタリア)、Medax Medical Devices(イタリア)です。

リサーチカバレッジ
当レポートでは、乳房病変部局在化市場を分析し、タイプ、用途、地域などの様々なセグメントに基づいて、同市場の市場規模と今後の成長性を推定することを目的としています。また、市場で販売されている様々な乳房病変部局在化製品の製品ポートフォリオマトリックスを掲載しています。また、この市場における主要企業の競争力分析を、企業プロフィール、製品内容、主要な市場戦略などとともに掲載しています。
レポートを購入する理由
本レポートは、既存の企業だけでなく、新規参入企業や小規模企業にとっても、市場の動向を把握するのに役立ち、市場でより大きなシェアを獲得するのに役立つでしょう。本レポートを購入した企業は、市場における自社のポジションを強化するために、以下の戦略の1つまたは複数の組み合わせを利用することができます。
本レポートでは、以下の点について分析しています。
- 市場への浸透。世界の乳房病変局在化市場のトッププレーヤーが提供する製品ポートフォリオに関する包括的な情報。本レポートでは、この市場をタイプ別、用途別、地域別に分析しています
- 製品の強化/革新。世界の乳房病変部局在化市場における今後のトレンドと製品の発売に関する詳細な洞察
- 市場の発展。タイプ別、用途別、地域別の有利な新興市場に関する包括的な情報
- 市場の多様化世界の乳房病変部局在化市場における新製品や製品の強化、成長地域、最近の開発状況、投資に関する詳細な情報
- 競合他社の評価。世界の乳房病変局在化市場における主要企業の市場シェア、成長戦略、製品提供、競争力のあるリーダーシップマッピング、能力などの詳細な評価。

1 INTRODUCTION 29
1.1 OBJECTIVES OF THE STUDY 29
1.2 MARKET DEFINITION 29
1.3 INCLUSIONS & EXCLUSIONS OF THE STUDY 30
1.4 SCOPE OF THE STUDY 30
1.4.1 MARKETS COVERED 30
FIGURE 1 GLOBAL BREAST LESION LOCALIZATION MARKET 30
1.4.2 YEARS CONSIDERED FOR THE STUDY 31
1.5 CURRENCY 31
1.6 STAKEHOLDERS 31
1.7 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 2 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 34
2.1.1.1 Key data from secondary sources 35
2.1.2 PRIMARY DATA 36
FIGURE 3 PRIMARY SOURCES 36
2.1.2.1 Key data from primary sources 37
2.1.2.2 Key industry insights 37
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 38
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND
DEMAND SIDE PARTICIPANTS 38
2.2 MARKET SIZE ESTIMATION 39
FIGURE 6 SUPPLY SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 40
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: 40
FIGURE 8 REVENUE ANALYSIS OF THE TOP FOUR COMPANIES: BREAST LESION LOCALIZATION MARKET (2020) 41
FIGURE 9 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE BREAST LESION LOCALIZATION MARKET (2021–2026) 43
FIGURE 10 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 43
FIGURE 11 TOP-DOWN APPROACH 44
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 45
FIGURE 12 MARKET DATA TRIANGULATION METHODOLOGY 45
2.4 MARKET SHARE ESTIMATION 45
2.5 ASSUMPTIONS FOR THE STUDY 46
2.6 RISK ASSESSMENT 46
TABLE 1 RISK ASSESSMENT: BREAST LESION LOCALIZATION MARKET 46
2.7 LIMITATIONS 47
2.7.1 METHODOLOGY-RELATED LIMITATIONS 47
2.7.2 SCOPE-RELATED LIMITATIONS 47
3 EXECUTIVE SUMMARY 48
FIGURE 13 BREAST LESION LOCALIZATION MARKET, BY TYPE,
2021 VS. 2026 (THOUSAND PROCEDURES) 48
FIGURE 14 BREAST LESION LOCALIZATION MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 49
FIGURE 15 RADIOISOTOPE LOCALIZATION MARKET, BY TYPE,
2021 VS. 2026 (THOUSAND PROCEDURES) 50
FIGURE 16 RADIOISOTOPE LOCALIZATION MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 50
FIGURE 17 BREAST LESION LOCALIZATION MARKET, BY USAGE,
2021 VS. 2026 (THOUSAND PROCEDURES) 51
FIGURE 18 BREAST LESION LOCALIZATION MARKET, BY USAGE,
2021 VS. 2026 (USD MILLION) 52
FIGURE 19 GEOGRAPHIC ANALYSIS: GLOBAL BREAST LESION LOCALIZATION MARKET (BASED ON PROCEDURE) 53
FIGURE 20 GEOGRAPHIC ANALYSIS: GLOBAL BREAST LESION LOCALIZATION MARKET (BASED ON VALUE) 54
4 PREMIUM INSIGHTS 56
4.1 BREAST LESION LOCALIZATION MARKET OVERVIEW 56
FIGURE 21 RISING AWARENESS TO DRIVE MARKET GROWTH 56
4.2 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY TYPE 57
FIGURE 22 WIRE LOCALIZATION TO HOLD THE LARGEST SHARE OF THE ASIA PACIFIC BREAST LESION LOCALIZATION MARKET IN 2020 57
4.3 BREAST LESION LOCALIZATION MARKET (BASED ON VALUE): GEOGRAPHIC GROWTH OPPORTUNITIES 58
FIGURE 23 APAC COUNTRIES TO WITNESS THE HIGHEST GROWTH IN THE BREAST LESION LOCALIZATION MARKET DURING THE FORECAST PERIOD 58
4.4 BREAST LESION LOCALIZATION MARKET, BY REGION 59
FIGURE 24 NORTH AMERICA TO DOMINATE THE BREAST LESION
LOCALIZATION MARKET TILL 2026 59
4.5 BREAST LESION LOCALIZATION MARKET: DEVELOPED VS. DEVELOPING MARKETS (THOUSAND PROCEDURES) 60
FIGURE 25 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE IN THE FORECAST PERIOD 60
5 MARKET OVERVIEW 61
5.1 MARKET DYNAMICS 62
FIGURE 26 BREAST LESION LOCALIZATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62
5.1.1 MARKET DRIVERS 62
5.1.1.1 Increasing incidence of breast cancer 62
TABLE 2 TOP 10 COUNTRIES WITH THE HIGHEST INCIDENCE OF
BREAST CANCER, 2020 63
FIGURE 27 ESTIMATED GLOBAL NUMBER OF NEW CASES OF BREAST
CANCER FROM 2020–2040 64
5.1.1.2 Growing rate of the aging population 64
5.1.1.3 Increasing awareness on the early detection of breast cancer 64
5.1.2 MARKET RESTRAINTS 65
5.1.2.1 Uncertainty in regulatory approval procedures 65
5.1.3 OPPORTUNITIES 66
5.1.3.1 Emerging economies offer high growth potential 66
5.1.3.2 Increasing adoption of technologically advanced localization procedures 66
5.1.4 CHALLENGES 67
5.1.4.1 Shortage of oncologists 67
6 INDUSTRY INSIGHTS 68
6.1 INDUSTRY TRENDS 68
6.1.1 ELECTROMAGNETIC WAVES FOR THE LOCALIZATION OF BREAST LESIONS 68
6.1.2 RADIOFREQUENCY IDENTIFICATION IN BREAST LESION LOCALIZATION 68
6.1.3 MACHINE LEARNING ALGORITHMS FOR COMPUTER-AIDED
BREAST LESION DETECTION 69
6.2 IMPACT OF COVID-19 ON THE BREAST LESION LOCALIZATION MARKET: RESTRUCTURING OF BREAST CANCER CARE 69
6.3 VALUE CHAIN ANALYSIS 71
6.4 REIMBURSEMENT ANALYSIS 72
TABLE 3 MEDICARE REIMBURSEMENT FOR BREAST LESION LOCALIZATION METHODS 73
6.5 TECHNOLOGY ANALYSIS 74
6.5.1 KEY TECHNOLOGIES 74
6.5.1.1 Wire guided localization (WL) 74
6.5.1.2 Carbon making 74
6.5.1.3 Radio-guided occult lesion localization (ROLL) 75
6.5.1.4 Radioactive seed localization (RSL) 75
6.5.1.5 Magnetic seed localization (MSL) 75
6.5.1.6 Radio frequency reflector (RFR) 75
6.5.2 COMPLEMENTARY TECHNOLOGIES 76
6.5.2.1 Mammography 76
6.5.2.2 3D Mammography or Tomosynthesis 76
6.5.2.3 Magnetic resonance imaging 76
6.5.2.4 Ultrasound 76
6.5.3 ADJACENT TECHNOLOGIES 76
6.5.3.1 Computer vision and artificial intelligence 76
 
6.6 PORTER’S FIVE FORCES ANALYSIS 77
TABLE 4 BREAST LESION LOCALIZATION MARKET: PORTER’S FIVE FORCES ANALYSIS 77
6.6.1 INTENSITY OF COMPETITIVE RIVALRY 77
6.6.2 BARGAINING POWER OF SUPPLIERS 77
6.6.3 BARGAINING POWER OF BUYERS 78
6.6.4 THREAT OF SUBSTITUTES 78
6.6.5 THREAT OF NEW ENTRANTS 78
6.7 REGULATORY ANALYSIS 79
6.7.1 NORTH AMERICA 79
6.7.1.1 US 79
TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION 79
TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 79
6.7.1.2 Canada 80
TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 80
TABLE 8 BREAST LESION LOCALIZATION DEVICES CLASSIFICATION ACCORDING TO THE GOVERNMENT OF CANADA 80
6.7.2 EUROPE 81
FIGURE 28 EUROPE: CLASS III MEDICAL DEVICES 81
6.7.3 ASIA PACIFIC 82
6.7.3.1 India 82
6.8 PATENT ANALYSIS 82
6.8.1 PATENT PUBLICATION TRENDS FOR BREAST LESIONS 82
FIGURE 29 PATENT PUBLICATION TRENDS (JANUARY 2011–DECEMBER 2021) 82
6.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 83
FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR BREAST LESION PATENTS (JANUARY 2011–DECEMBER 2021) 83
FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR BREAST LESION PATENTS (JANUARY 2011–DECEMBER 2021) 84
7 BREAST LESION LOCALIZATION MARKET, BY TYPE 85
7.1 INTRODUCTION 86
TABLE 9 BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 86
TABLE 10 BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 86
7.2 COVID-19 IMPACT ON THE BREAST LESION LOCALIZATION MARKET, BY TYPE 87
7.3 WIRE LOCALIZATION 87
7.3.1 WIRE LOCALIZATION SEGMENT TO COMMAND THE LARGEST SHARE OF THE BREAST LESION LOCALIZATION MARKET 87
TABLE 11 WIRE LOCALIZATION MARKET, BY COUNTRY,
2019–2026 (THOUSAND PROCEDURES) 88
TABLE 12 WIRE LOCALIZATION PRODUCTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 89
 
7.4 RADIOISOTOPE LOCALIZATION 89
TABLE 13 RADIOISOTOPE LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 90
TABLE 14 RADIOISOTOPE LOCALIZATION PRODUCTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 90
TABLE 15 RADIOISOTOPE LOCALIZATION MARKET, BY COUNTRY,
2019–2026 (THOUSAND PROCEDURES) 91
TABLE 16 RADIOISOTOPE LOCALIZATION PRODUCTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 92
7.4.1 RADIOGUIDED OCCULT LESION LOCALIZATION (ROLL) 92
7.4.1.1 ROLL to result in shorter operating times, higher rates of tumor-free margins, and lower rates of re-operation 92
TABLE 17 RADIOGUIDED OCCULT LESION LOCALIZATION MARKET, BY COUNTRY,
2019–2026 (THOUSAND PROCEDURES) 93
TABLE 18 RADIOGUIDED OCCULT LESION LOCALIZATION PRODUCTS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 94
7.4.2 RADIOACTIVE SEED LOCALIZATION (RSL) 94
7.4.2.1 Reduction in re-excision rates, decreased operative time, and long half-life of RSL to drive market growth 94
TABLE 19 RADIOACTIVE SEED LOCALIZATION MARKET, BY COUNTRY,
2019–2026 (THOUSAND PROCEDURES) 95
TABLE 20 RADIOACTIVE SEED LOCALIZATION PRODUCTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 96
7.5 MAGNETIC LOCALIZATION 96
7.5.1 MAGNETIC LOCALIZATION TECHNIQUE TO INCREASE WORKFLOW EFFICIENCY AND COST-EFFECTIVENESS, ELIMINATE ISSUES RELATED TO NONRADIOACTIVE TECHNOLOGY, AND IMPROVE SURGICAL PLANNING 96
TABLE 21 MAGNETIC LOCALIZATION MARKET, BY COUNTRY,
2019–2026 (THOUSAND PROCEDURES) 97
TABLE 22 MAGNETIC LOCALIZATION PRODUCTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 98
7.6 ELECTROMAGNETIC LOCALIZATION 98
7.6.1 ELECTROMAGNETIC LOCALIZATION TO MAKE SMALLER INCISIONS TO BE MORE PRECISE AND SAVE MORE OF THE NORMAL TISSUE DURING SURGERIES 98
TABLE 23 ELECTROMAGNETIC LOCALIZATION MARKET, BY COUNTRY,
2019–2026 (THOUSAND PROCEDURES) 99
TABLE 24 ELECTROMAGNETIC LOCALIZATION PRODUCTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 100
7.7 OTHER LOCALIZATION METHODS 101
TABLE 25 OTHER LOCALIZATION METHODS MARKET, BY COUNTRY,
2019–2026 (THOUSAND PROCEDURES) 101
TABLE 26 OTHER LOCALIZATION PRODUCTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 102
 
8 BREAST LESION LOCALIZATION MARKET, BY USAGE 103
8.1 INTRODUCTION 104
TABLE 27 BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 104
TABLE 28 BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 105
8.2 BREAST BIOPSY 105
8.2.1 BREAST BIOPSY SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE BREAST LESION LOCALIZATION MARKET BY USAGE 105
TABLE 29 BREAST LESION LOCALIZATION MARKET FOR BREAST BIOPSY, BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES) 106
TABLE 30 BREAST LESION LOCALIZATION MARKET FOR BREAST BIOPSY, BY COUNTRY, 2019–2026 (USD MILLION) 107
8.3 BREAST CONSERVATION (LUMPECTOMY) 107
8.3.1 INCREASING ADOPTION OF BREAST CONSERVATION THERAPY TO DRIVE THE GROWTH OF BREAST LESION LOCALIZATION MARKET 107
TABLE 31 BREAST LESION LOCALIZATION MARKET FOR BREAST CONSERVATION,
BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES) 108
TABLE 32 BREAST LESION LOCALIZATION MARKET FOR BREAST CONSERVATION,
BY COUNTRY, 2019–2026 (USD MILLION) 109
9 BREAST LESION LOCALIZATION MARKET, BY REGION 110
9.1 INTRODUCTION 111
FIGURE 32 NUMBER OF BREAST CANCER CASES VS NUMBER OF DEATHS
IN 2020 (IN THOUSANDS) 111
TABLE 33 BREAST LESION LOCALIZATION MARKET, BY REGION,
2019–2026 (THOUSAND PROCEDURES) 112
TABLE 34 BREAST LESION LOCALIZATION MARKET, BY REGION,
2019–2026 (USD MILLION) 112
9.2 NORTH AMERICA 113
FIGURE 33 NORTH AMERICA: NUMBER OF BREAST CANCER
CASES 2020 (IN THOUSANDS) 113
TABLE 35 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY COUNTRY, 2019–2026 (THOUSAND PROCEDURES) 115
TABLE 36 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 115
TABLE 37 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 116
TABLE 38 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 116
TABLE 39 NORTH AMERICA: RADIOISOTOPE LOCALIZATION METHODS MARKET,
BY TYPE, 2019–2026 (THOUSAND PROCEDURES) 117
TABLE 40 NORTH AMERICA: RADIOISOTOPE LOCALIZATION METHODS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 117
TABLE 41 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2019–2026 (THOUSAND PROCEDURES) 118
TABLE 42 NORTH AMERICA: BREAST LESION LOCALIZATION MARKET, BY USAGE, 2019–2026 (USD MILLION) 118
9.2.1 US 119
TABLE 43 US: KEY MACROINDICATORS 119
TABLE 44 US: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 120
TABLE 45 US: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 120
TABLE 46 US: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 121
TABLE 47 US: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (USD MILLION) 121
TABLE 48 US: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 122
TABLE 49 US: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 122
9.2.2 CANADA 123
TABLE 50 CANADA: KEY MACROINDICATORS 123
TABLE 51 CANADA: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 124
TABLE 52 CANADA: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 124
TABLE 53 CANADA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 125
TABLE 54 CANADA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (USD MILLION) 125
TABLE 55 CANADA: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 126
TABLE 56 CANADA: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 126
9.3 EUROPE 127
FIGURE 35 EUROPE: NUMBER OF BREAST CANCER CASES, 2020 (IN THOUSANDS) 127
TABLE 57 EUROPE: BREAST LESION LOCALIZATION MARKET, BY COUNTRY,
2019–2026 (THOUSAND PROCEDURES) 129
TABLE 58 EUROPE: BREAST LESION LOCALIZATION MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 129
TABLE 59 EUROPE: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 130
TABLE 60 EUROPE: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 130
TABLE 61 EUROPE: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 131
TABLE 62 EUROPE: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (USD MILLION) 131
TABLE 63 EUROPE: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 132
TABLE 64 EUROPE: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 132
9.3.1 GERMANY 132
TABLE 65 GERMANY: KEY MACROINDICATORS 133
TABLE 66 GERMANY: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 133
TABLE 67 GERMANY: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 134
TABLE 68 GERMANY: RADIOISOTOPE LOCALIZATION METHODS MARKET,
BY TYPE, 2019–2026 (THOUSAND PROCEDURES) 134
TABLE 69 GERMANY: RADIOISOTOPE LOCALIZATION METHODS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 135
TABLE 70 GERMANY: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 135
TABLE 71 GERMANY: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 136
9.3.2 FRANCE 136
TABLE 72 FRANCE: KEY MACROINDICATORS 137
TABLE 73 FRANCE: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 137
TABLE 74 FRANCE: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 138
TABLE 75 FRANCE: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 138
TABLE 76 FRANCE: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (USD MILLION) 139
TABLE 77 FRANCE: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 139
TABLE 78 FRANCE: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 140
9.3.3 UK 140
TABLE 79 UK: KEY MACROINDICATORS 141
TABLE 80 UK: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 141
TABLE 81 UK: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 142
TABLE 82 UK: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 142
TABLE 83 UK: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (USD MILLION) 143
TABLE 84 UK: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 143
TABLE 85 UK: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 144
9.3.4 ITALY 144
TABLE 86 ITALY: KEY MACROINDICATORS 145
TABLE 87 ITALY: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 145
TABLE 88 ITALY: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 146
TABLE 89 ITALY: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 146
TABLE 90 ITALY: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (USD MILLION) 147
TABLE 91 ITALY: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 147
TABLE 92 ITALY: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 148
9.3.5 SPAIN 148
TABLE 93 SPAIN: KEY MACROINDICATORS 149
TABLE 94 SPAIN: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 149
TABLE 95 SPAIN: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 150
TABLE 96 SPAIN: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 150
TABLE 97 SPAIN: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (USD MILLION) 151
TABLE 98 SPAIN: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 151
TABLE 99 SPAIN: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 152
9.3.6 REST OF EUROPE 152
TABLE 100 ROE: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 153
TABLE 101 ROE: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 153
TABLE 102 ROE: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 154
TABLE 103 ROE: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (USD MILLION) 154
TABLE 104 ROE: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 155
TABLE 105 ROE: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 155
9.4 ASIA PACIFIC 156
FIGURE 37 APAC: NUMBER OF BREAST CANCER CASES, 2020 (IN THOUSANDS) 156
TABLE 106 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY COUNTRY,
2019–2026 (THOUSAND PROCEDURES) 158
TABLE 107 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 158
TABLE 108 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 159
TABLE 109 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 159
TABLE 110 ASIA PACIFIC: RADIOISOTOPE LOCALIZATION METHODS MARKET,
BY TYPE, 2019–2026 (THOUSAND PROCEDURES) 160
TABLE 111 ASIA PACIFIC: RADIOISOTOPE LOCALIZATION METHODS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 160
TABLE 112 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 161
TABLE 113 ASIA PACIFIC: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 161
9.4.1 CHINA 162
TABLE 114 CHINA: KEY MACROINDICATORS 162
TABLE 115 CHINA: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 163
TABLE 116 CHINA: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 163
TABLE 117 CHINA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 164
TABLE 118 CHINA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (USD MILLION) 164
TABLE 119 CHINA: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 165
TABLE 120 CHINA: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 165
9.4.2 JAPAN 166
TABLE 121 JAPAN: KEY MACROINDICATORS 166
TABLE 122 JAPAN: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 167
TABLE 123 JAPAN: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 167
TABLE 124 JAPAN: RADIOISOTOPE LOCALIZATION METHODS MARKET,
BY TYPE, 2019–2026 (THOUSAND PROCEDURES) 168
TABLE 125 JAPAN: RADIOISOTOPE LOCALIZATION METHODS MARKET,
BY TYPE, 2019–2026 (USD MILLION) 168
TABLE 126 JAPAN: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 169
TABLE 127 JAPAN: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 169
9.4.3 INDIA 170
TABLE 128 INDIA: KEY MACROINDICATORS 170
TABLE 129 INDIA: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 171
TABLE 130 INDIA: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 171
TABLE 131 INDIA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 172
TABLE 132 INDIA: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (USD MILLION) 172
TABLE 133 INDIA: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 173
TABLE 134 INDIA: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 173
9.4.4 REST OF APAC 174
TABLE 135 ROAPAC: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 174
TABLE 136 ROAPAC: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 175
TABLE 137 ROAPAC: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 175
TABLE 138 ROAPAC: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (USD MILLION) 176
TABLE 139 ROAPAC: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 176
TABLE 140 ROAPAC: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 177
9.5 REST OF THE WORLD 177
TABLE 141 ROW: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 178
TABLE 142 ROW: BREAST LESION LOCALIZATION MARKET, BY TYPE,
2019–2026 (USD MILLION) 178
TABLE 143 ROW: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (THOUSAND PROCEDURES) 179
TABLE 144 ROW: RADIOISOTOPE LOCALIZATION METHODS MARKET, BY TYPE,
2019–2026 (USD MILLION) 179
TABLE 145 ROW: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (THOUSAND PROCEDURES) 180
TABLE 146 ROW: BREAST LESION LOCALIZATION MARKET, BY USAGE,
2019–2026 (USD MILLION) 180
10 COMPETITIVE LANDSCAPE 181
10.1 OVERVIEW 181
10.2 KEY PLAYER STRATEGIES 181
10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 182
FIGURE 39 REVENUE ANALYSIS OF THE TOP PLAYERS IN THE BREAST LESION LOCALIZATION MARKET 182
10.4 MARKET SHARE ANALYSIS 183
FIGURE 40 GLOBAL BREAST LESION LOCALIZATION MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2020 183
10.5 COMPANY EVALUATION QUADRANT 184
10.5.1 STARS 184
10.5.2 EMERGING LEADERS 184
10.5.3 PERVASIVE PLAYERS 184
10.5.4 PARTICIPANTS 185
FIGURE 41 BREAST LESION LOCALIZATION MARKET: COMPANY EVALUATION QUADRANT (2020) 185
10.6 COMPANY EVALUATION QUADRANT FOR START-UPS 186
10.6.1 PROGRESSIVE COMPANIES 186
10.6.2 DYNAMIC COMPANIES 186
10.6.3 STARTING BLOCKS 186
10.6.4 RESPONSIVE COMPANIES 186
FIGURE 42 BREAST LESION LOCALIZATION MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS (2020) 187
10.7 COMPANY PRODUCT FOOTPRINT 188
TABLE 147 PRODUCT PORTFOLIO ANALYSIS: BREAST LESION LOCALIZATION MARKET 188
10.8 GEOGRAPHIC FOOTPRINT OF THE MAJOR PLAYERS IN THE BREAST LESION LOCALIZATION MARKET 189
TABLE 148 GEOGRAPHIC REVENUE MIX: BREAST LESION LOCALIZATION MARKET (2020) 189
10.9 COMPETITIVE SCENARIO 190
10.9.1 DEALS 190
TABLE 149 DEALS 190
10.9.2 PRODUCT LAUNCHES AND UPGRADES 191
TABLE 150 PRODUCT LAUNCHES AND UPGRADES 191
10.10 BREAST LESION LOCALIZATION METHODS: COMPARATIVE ANALYSIS 191
10.11 BREAST LESION LOCALIZATION METHODS: COMPARATIVE ANALYSIS 193
10.12 BREAST LESION LOCALIZATION METHODS: SELECTION CRITERIA EVALUATION 193
10.13 QUALITATIVE ASSESSMENT OF REPLACEMENT TRENDS 194
11 COMPANY PROFILES 196
11.1 KEY PLAYERS 196
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 HOLOGIC, INC. 196
TABLE 151 HOLOGIC, INC.: BUSINESS OVERVIEW 196
FIGURE 46 HOLOGIC, INC.: COMPANY SNAPSHOT (2020) 197
11.1.2 BECTON, DICKINSON AND COMPANY 200
TABLE 152 BECTON, DICKINSON, AND COMPANY: BUSINESS OVERVIEW 200
FIGURE 47 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 201
11.1.3 MERIT MEDICAL SYSTEMS 203
TABLE 153 MERIT MEDICAL SYSTEMS: BUSINESS OVERVIEW 203
FIGURE 48 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2020) 204
11.1.4 LEICA BIOSYSTEMS NUSSLOCH GMBH 206
TABLE 154 DANAHER CORPORATION: BUSINESS OVERVIEW 206
FIGURE 49 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 207
11.1.5 ARGON MEDICAL DEVICES 209
TABLE 155 ARGON MEDICAL DEVICES: BUSINESS OVERVIEW 209
11.1.6 LAURANE MEDICAL LLC 211
TABLE 156 LAURANE MEDICAL LLC: BUSINESS OVERVIEW 211
11.1.7 ENDOMAGNETICS LTD. (ENDOMAG) 212
TABLE 157 ENDOMAGNETICS LIMITED: BUSINESS OVERVIEW 212
11.1.8 INTRAMEDICAL IMAGING, LLC 213
TABLE 158 INTRAMEDICAL IMAGING, LLC: BUSINESS OVERVIEW 213
11.1.9 ISOAID 214
TABLE 159 ISOAID: BUSINESS OVERVIEW 214
11.1.10 SURGICEYE GMBH 215
TABLE 160 SURGICEYE GMBH: BUSINESS OVERVIEW 215
11.2 OTHER PLAYERS 217
11.2.1 RANFAC CORP. 217
TABLE 161 RANFAC CORP.: BUSINESS OVERVIEW 217
11.2.2 MERMAID MEDICAL GROUP 218
TABLE 162 MERMAID MEDICAL GROUP: BUSINESS OVERVIEW 218
11.2.3 IZI MEDICALPRODUCTS, LLC 219
TABLE 163 IZI MEDICAL PRODUCTS, LLC: BUSINESS OVERVIEW 219
11.2.4 MATEK MEDIKAL 220
TABLE 164 MATEK MEDIKAL: BUSINESS OVERVIEW 220
11.2.5 TSUNAMI MEDICAL SRL 221
TABLE 165 TSUNAMI MEDICAL SRL: BUSINESS OVERVIEW 221
11.2.6 BPB MEDICA 222
TABLE 166 BPB MEDICA: BUSINESS OVERVIEW 222
11.2.7 SIRIUS MEDICAL SYSTEMS B.V. 223
TABLE 167 SIRIUS MEDICAL SYSTEMS B.V.: BUSINESS OVERVIEW 223
11.2.8 MOLLI SURGICAL INC. 224
TABLE 168 MOLLI SURGICAL INC.: BUSINESS OVERVIEW 224
11.2.9 STERYLAB S.R.L. 225
TABLE 169 STERYLAB S.R.L.: BUSINESS OVERVIEW 225
11.2.10 CP MEDICAL 226
TABLE 170 CP MEDICAL: BUSINESS OVERVIEW 226
11.2.11 MDL SRL 227
TABLE 171 MDL SRL: BUSINESS OVERVIEW 227
11.2.12 BIOMEDICAL SRL 228
TABLE 172 BIOMEDICAL SRL: BUSINESS OVERVIEW 228
11.2.13 ELUCENT MEDICAL 229
TABLE 173 ELUCENT MEDICAL: BUSINESS OVERVIEW 229
11.2.14 VIGEO SRL 230
TABLE 174 VIGEO SRL: BUSINESS OVERVIEW 230
11.2.15 MEDAX MEDICAL DEVICES 231
TABLE 175 MEDAX MEDICAL DEVICES: BUSINESS OVERVIEW 231
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 232
12.1 DISCUSSION GUIDE 232
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 235
12.3 RELATED REPORTS 237
12.4 AUTHOR DETAILS 238